The Dual Agonist Breakthrough: Why Two Is Better Than One Tirzepatide, the first dual GLP-1/GIP agonist to reach market, demonstrated that activating both receptors produces superior results to activating GLP-1 alone
Heart failure with preserved ejection fraction (HFpEF) accounts for approximately half of all heart failure cases, with patients bearing a high symptomatic burden and physical limitations that impact their daily lives
In lieu of states expanding coverage, states that are committed to retaining coverage are looking at mechanisms to better control costs
CMS and manufacturers may renegotiate terms in the future depending on certain circumstances such as changes in the FDA labeling, new clinical evidence, or new products launched
(NIDDK) I also see a second misconception: that success on these medications is purely about eating less. In reality, the reason many patients do better with GLP-1-based treatment is that these medications can change the biology driving overeating, poor fullness signaling, and dysregulated blood sugar
Targeting cAMP/PKA pathway for glycemic control and type 2 diabetes therapy
